Fig. 2
From: FGF18 alleviates sepsis-induced acute lung injury by inhibiting the NF-κB pathway
FGF18 alleviates lung injury in the ALI mouse model. (A) Schematic diagram demonstrates the animal experiment design. (B) Western blotting was performed and quantitatively analyzed to determine the protein levels of FGF18 in the lungs from AAV-FGF18 and AAV-LacZ-treated controls. (n = 5 per group). (C) Immunofluorescent staining of FGF18 (red) and DAPI (blue) in AAV-FGF18 or AAV-LacZ-treated mice were detected. (Scale bar = 150 μm). (D) HE staining in lung tissues of AAV-FGF18 and AAV-LacZ-treated mice after PBS or LPS injection for 12 h. (n = 6 per group, Scale bar = 50 μm). (E) Western blotting was performed and quantitatively analyzed to determine the protein levels of VCAM-1, ICAM-1, IL-6, and TNF-α in the lungs from AAV-FGF18 and AAV-LacZ-treated controls. (n = 6 per group). (F) Immunofluorescent staining of ICAM-1/VCAM-1 (red) and DAPI (blue) in AAV-FGF18 and AAV-LacZ-treated mice were detected. (n = 6 per group, Scale bar = 150 μm)